NASDAQ:MRKR Marker Therapeutics (MRKR) Stock Price, News & Analysis → Elon to Transform U.S. Economy? (From Porter & Company) (Ad) Free MRKR Stock Alerts $4.15 +0.05 (+1.22%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$4.10▼$4.2550-Day Range$3.98▼$4.9152-Week Range$1.16▼$9.68Volume7,302 shsAverage Volume11,192 shsMarket Capitalization$37.02 millionP/E RatioN/ADividend YieldN/APrice Target$11.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Marker Therapeutics alerts: Email Address Marker Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside165.1% Upside$11.00 Price TargetShort InterestHealthy0.84% of Float Sold ShortDividend StrengthN/ASustainability-0.75Upright™ Environmental ScoreNews Sentiment0.04Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.20 out of 5 starsMedical Sector153rd out of 918 stocksPharmaceutical Preparations Industry60th out of 424 stocks 3.5 Analyst's Opinion Consensus RatingMarker Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageMarker Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Marker Therapeutics' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.84% of the float of Marker Therapeutics has been sold short.Short Interest Ratio / Days to CoverMarker Therapeutics has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Marker Therapeutics has recently decreased by 16.30%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMarker Therapeutics does not currently pay a dividend.Dividend GrowthMarker Therapeutics does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMarker Therapeutics has received a 53.36% net impact score from Upright. Marker Therapeutics seems to create the most significant positive value in categories "Jobs", "Creating knowledge", and "Physical diseases". The positive contribution in the "Creating knowledge" impact category is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Marker Therapeutics is -0.75. Previous Next 2.2 News and Social Media Coverage News SentimentMarker Therapeutics has a news sentiment score of 0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Marker Therapeutics this week, compared to 1 article on an average week.Search Interest1 people have searched for MRKR on MarketBeat in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Marker Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders24.10% of the stock of Marker Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 22.39% of the stock of Marker Therapeutics is held by institutions.Read more about Marker Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Marker Therapeutics are expected to remain at ($1.28) per share in the coming year.Price to Book Value per Share RatioMarker Therapeutics has a P/B Ratio of 3.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Marker Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 Media[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Are you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealthy beyond your wildest dreams. You see, while Bitcoin and Ethereum steal all the headlines… It’s often the cryptos flying under the radar that turn small stakes into life-changing windfalls. Claim your free seat by clicking here now. About Marker Therapeutics Stock (NASDAQ:MRKR)Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells. The company also develops MT-401-OTS, which is in phase 1 clinical trial for the treatment of acute myeloid leukemia; and MT-601 which is in phase 1 clinical trial for the treatment of lymphoma, as well as in phase 1/2 clinical trial for the treatment of pancreatic cancer. Marker Therapeutics is headquartered in Houston, Texas.Read More MRKR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MRKR Stock News HeadlinesMay 16 at 2:42 PM | msn.comCombining two tumor markers can help track down colorectal cancer subtypesMay 16 at 1:12 AM | investorplace.comMRKR Stock Earnings: Marker Therapeutics Reported Results for Q1 2024May 15 at 4:15 PM | globenewswire.comMarker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdatesMay 13, 2024 | msn.comReinstalling a Midstate MarkerMay 13, 2024 | msn.comFatal collision occurs on SH 176 at Mile Marker 240 in Andrews CountyMay 2, 2024 | uk.investing.comMarker Therapeutics stock gets Buy from Ladenburg citing CAR-T therapy potentialMay 2, 2024 | benzinga.comMarker Therapeutics Stock (NASDAQ:MRKR), Analyst Ratings, Price Targets, PredictionsMay 1, 2024 | msn.comLadenburg Thalmann Initiates Coverage of Marker Therapeutics (MRKR) with Buy RecommendationApril 30, 2024 | msn.comMile Marker 158 Dockside - Orange Beach, ALApril 27, 2024 | msn.com‘Useful way of marking history’: National Historic Marker Day asks residents to clean off local signsApril 27, 2024 | msn.com'Useful way of marking history': National Historic Marker Day asks residents to clean off local signsApril 10, 2024 | investing.comMarker Therapeutics Inc (MRKR)April 9, 2024 | msn.comPutnam Marker Honoring Warner Sisters Restored At Foundry Point ParkApril 8, 2024 | globenewswire.comPrincipal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic MalignanciesApril 3, 2024 | finance.yahoo.comGlobal Cardiac Marker Testing Market Sees Robust Growth with Rising Incidence of Cardiovascular DiseasesMarch 26, 2024 | msn.comMarker Therapeutics GAAP EPS of -$1.59, revenue of $3.31MMarch 25, 2024 | globenewswire.comMarker Therapeutics Reports Year-End 2023 Corporate and Financial ResultsMarch 22, 2024 | globenewswire.comMarker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual ConferenceMarch 22, 2024 | msn.comJudge Dismisses Lawsuit Over Removal of Marker Dedicated to Communist Party LeaderMarch 14, 2024 | finance.yahoo.comGlobal Marker Pens Market Projected to Reach $492.3 Million by 2030, Driven by a Robust CAGR of 5.2%March 13, 2024 | msn.comEliminate Marker Stains From Brick Surfaces With A Handy Hydrogen Peroxide TrickMarch 12, 2024 | finance.yahoo.comNimbus Therapeutics Appoints Katharine Knobil, M.D., to Board of DirectorsFebruary 16, 2024 | usatoday.comLegislators: Why are women overlooked for Florida's Historical Marker Program?February 3, 2024 | msn.comEXPO Low Odor Dry Erase Marker Starter Set, Now 29% OffJanuary 22, 2024 | finance.yahoo.comMarker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601See More Headlines Receive MRKR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Marker Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today5/18/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MRKR CUSIPN/A CIK1094038 Webwww.markertherapeutics.com Phone(713) 400-6400FaxN/AEmployees8Year Founded2018Price Target and Rating Average Stock Price Target$11.00 High Stock Price Target$11.00 Low Stock Price Target$11.00 Potential Upside/Downside+165.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,240,000.00 Net Margins-142.62% Pretax Margin-424.10% Return on Equity-39.89% Return on Assets-25.45% Debt Debt-to-Equity RatioN/A Current Ratio6.12 Quick Ratio5.57 Sales & Book Value Annual Sales$3.31 million Price / Sales11.18 Cash FlowN/A Price / Cash FlowN/A Book Value$1.32 per share Price / Book3.14Miscellaneous Outstanding Shares8,920,000Free Float6,765,000Market Cap$37.02 million OptionableNot Optionable Beta1.54 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. Juan F. Vera M.D. (Age 43)Co-Founder, CEO, President, Treasurer & Director Comp: $529.12kMs. Elizabeth DonnellyDirector of AdministrationMr. Edmund CheungVice President of Human ResourcesDr. Nadia Agopyan Ph.D.Senior Vice President of Regulatory AffairsDr. Monic Stuart M.D.Chief Medical OfficerPatricia AllisonHead of Clinical OperationsMr. Michael J. Loiacono (Age 58)Secretary Comp: $287.98kDr. Robert Z. Florkiewicz Sr.Senior Director of Molecular Biology & VirologyMore ExecutivesKey CompetitorsSatsuma PharmaceuticalsNASDAQ:STSAProMIS NeurosciencesNASDAQ:PMNSensei BiotherapeuticsNASDAQ:SNSESpruce BiosciencesNASDAQ:SPRBFortress BiotechNASDAQ:FBIOView All Competitors MRKR Stock Analysis - Frequently Asked Questions Should I buy or sell Marker Therapeutics stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Marker Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MRKR shares. View MRKR analyst ratings or view top-rated stocks. What is Marker Therapeutics' stock price target for 2024? 1 equities research analysts have issued 1-year target prices for Marker Therapeutics' shares. Their MRKR share price targets range from $11.00 to $11.00. On average, they expect the company's stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 165.1% from the stock's current price. View analysts price targets for MRKR or view top-rated stocks among Wall Street analysts. How have MRKR shares performed in 2024? Marker Therapeutics' stock was trading at $5.50 at the beginning of the year. Since then, MRKR shares have decreased by 24.5% and is now trading at $4.15. View the best growth stocks for 2024 here. When is Marker Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our MRKR earnings forecast. How were Marker Therapeutics' earnings last quarter? Marker Therapeutics, Inc. (NASDAQ:MRKR) posted its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.12) earnings per share for the quarter, beating analysts' consensus estimates of ($0.13) by $0.01. Marker Therapeutics had a negative trailing twelve-month return on equity of 39.89% and a negative net margin of 142.62%. What other stocks do shareholders of Marker Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Marker Therapeutics investors own include Amarin (AMRN), Viking Therapeutics (VKTX), PhaseBio Pharmaceuticals (PHAS), SCYNEXIS (SCYX), Matinas BioPharma (MTNB), Genocea Biosciences (GNCA), Strongbridge Biopharma (SBBP), Flexion Therapeutics (FLXN), Geron (GERN) and Ionis Pharmaceuticals (IONS). How do I buy shares of Marker Therapeutics? Shares of MRKR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MRKR) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingObama’s Forever Term [exposed]Porter & Company4 Cryptos BETTER than BitcoinTrue Market InsidersElon’s New Device is About to Shock the WorldInvestorPlaceUrgent Nvidia WarningAltimetryForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressMissed NVDA? Buy this AI stock NOWChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Marker Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
